<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">FELODIPINE</span><br/>(fel-o'di-peen)<br/><span class="topboxtradename">Plendil<br/></span><b>Classifications:</b> <span class="classification">cardiovascular agent</span>; <span class="classification">calcium channel blocker</span><br/><b>Prototype: </b>Nifedipine<br/><b>Pregnancy Category: </b>C<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>2.5 mg, 5 mg, 10 mg sustained release tablets</p>
<h1><a name="action">Actions</a></h1>
<p>Calcium antagonist with high vascular selectivity that reduces systolic, diastolic, and mean arterial pressure at rest and
         during exercise.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>BP reduction is due to a reduction in peripheral vascular resistance (after-load) against which the heart works. This reduces
         oxygen demand by the heart and consequently may account for its effectiveness in chronic stable angina.
      </p>
<h1><a name="uses">Uses</a></h1>
<p>Mild to moderate hypertension.</p>
<h1><a name="unlabeleduses">Unlabeled Uses</a></h1>
<p>Severe hypertension, angina, CHF, pulmonary hypertension.</p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Hypersensitivity to felodipine and sick sinus rhythm or second- or third-degree heart block except with the use of a pacemaker.
         Safety and efficacy in children are not established.
      </p>
<h1><a name="precaution">Cautious Use</a></h1>
<p>Hypotension, CHF, hepatic impairment; pregnancy (category C), lactation.</p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Hypertension</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 510 mg once/d (max: 20 mg/d)<br/><br/><span class="impairmenttitle">Hepatic Impairment</span><br/>Start older adults and patients with impaired liver function at 2.5 mg q.d.<br/><br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1><span class="adminroutetype">Oral</span><br/><ul>
<li>Give tablet whole. Do not crush or chew tablets.</li>
<li>Store at or below 30° C (86° F) in a tightly closed, light-resistant container.</li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead"> Body as a Whole:</span> Most adverse effects appear to be dose dependent. <span class="typehead">CV:</span> Tachycardia, <span class="speceff-common">palpitations, flushing, peripheral edema.</span> <span class="typehead">CNS:</span> <span class="speceff-common">Dizziness, fatigue,</span> headache. <span class="typehead">GI:</span> Nausea, flatulence, diarrhea, dyspepsia. <span class="typehead">Hematologic:</span> Small but significant decreases in Hct, Hgb, and RBC count. 
      <h1><a name="dtintefer">Diagnostic Test Interference</a></h1>
<p>Serum <span class="alt">alkaline phosphatase</span> may be slightly but significantly increased. Plasma total and ionized <span class="alt">calcium</span> levels rise significantly. Serum <span class="alt">gamma-glutamyl transferase</span> may increase.
      </p>
<h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span> <b>Adenosine</b> may cause prolonged bradycardia if it is used to treat patients with toxic concentrations of <span class="classification">calcium channel blockers</span>. <b>Carbamazepine,</b> <b>phenobarbital,</b> <b>phenytoin</b> may decrease felodipine bioavailability and serum concentrations. <b>Cimetidine</b> may increase felodipine bioavailability (competes for hepatic metabolism). Concomitant felodipine and <b>digoxin</b> administration produces only transient increases in plasma <b>digoxin</b> concentrations (3540% increase), which are not sustained with continued administration. This interaction may be
      of clinical relevance in patients whose plasma <b>digoxin</b> concentration is in the upper portion of the therapeutic range or in patients with preexisting renal insufficiency. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Absorption:</span> Completely absorbed from GI tract; it undergoes extensive first-pass metabolism with only about 15% of dose reaching systemic
      circulation. <span class="typehead">Onset:</span> Peak: 24 h. <span class="typehead">Duration:</span> 2024 h (sustained release formulation). <span class="typehead"> Distribution:</span>  &gt;99% bound to plasma proteins. <span class="typehead">Metabolism:</span> Metabolized via hepatic cytochrome P-450 mixed function oxidase system. <span class="typehead">Elimination:</span> 6070% of metabolites are excreted in urine within 72 h. <span class="typehead">Half-Life:</span> 10 h. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Monitor BP carefully, especially at initiation of drug therapy, in patients &gt;64 y, and in those with impaired liver function.</li>
<li>Anticipate BP reduction with possible reflex heart rate increase (510 bpm) 25 h after dosing.</li>
<li>Report sustained hypotension promptly; more common with concurrent beta-blocker therapy.</li>
<li>Assess for and report reflex tachycardia; may precipitate angina.</li>
<li>Monitor patients for possible digoxin toxicity when taking concurrent digoxin.</li>
</ul>
<p><span class="eductitle">Patient Education</span></p>
<ul>
<li>Report peripheral edema, headache, or flushing to physician. These may necessitate discontinuation of drug.</li>
<li>Get up from lying down slowly and in stages; there is potential for dizziness and hypotension.</li>
<li>Do not breast feed while taking this drug without consulting physician.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>